Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Study save search
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $38.49 -2.88% -2.96% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
CMPX | $1.5 -1.96% -2.0% 240K
|
Professional, Scientific, and T...
|
| O: 2.93%
H: 3.8%
C: -0.63%
ctx-8371 first tumors therapeutics study
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
NMRA | $10.54 0.67% 0.66% 400K
|
|
| O: -20.17%
H: 11.46%
C: 0.99%
nmra-266 therapeutics study
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Published: 2024-04-12 (Crawled : 20:00) - globenewswire.com
AQST | $4.505 14.92% 12.99% 5.8M
|
Health Technology
| Email alert
Add to watchlist
neurology for meeting therapeutics study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
MDNAF | $1.27 -17.54% 140K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 ongoing expansion results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.27 -17.54% 140K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.27 -17.54% 140K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.36 -0.59% -0.6% 150K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CTMX | $1.735 -1.42% -1.44% 200K
|
Health Technology
|
| O: 1.21%
H: 0.48%
C: -1.44%
cx-2051 first tumors therapeutics advanced study
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
MRKR | $4.24 -1.62% -1.65% 13K
|
Consumer Services
|
| O: -5.73%
H: 5.86%
C: 2.17%
hope city global medical therapeutics study
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $8.07 -13.23% -15.24% 43K
|
| Email alert
Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
APLT A | $4.74 -1.86% -1.9% 720K
|
Health Technology
|
| O: -2.35%
H: 7.72%
C: -4.82%
therapeutics results study diabetic
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K
|
Health Technology
|
| O: 2.25%
H: 4.0%
C: 1.0%
alg-0550 first therapeutics study
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.69 0.43% 0.43% 200K
|
Health Technology
|
| O: -2.27%
H: 0.0%
C: 0.0%
positive treatment results study
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
AVRO | $1.23 0.82% 0.81% 37K
|
Health Technology
|
| O: 2.46%
H: 1.6%
C: 0.8%
tx45 group hypertension heart study
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.23 0.0% 20K
|
Health Technology
|
| O: 21.74%
H: 19.29%
C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
SEEL | $0.322 -3.01% -3.11% 270K
|
Health Technology
|
| O: -54.24%
H: 71.43%
C: 54.76%
sls-005 update sclerosis therapeutics results study
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: -1.29%
H: 9.86%
C: 6.93%
first urticaria therapeutics study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.